Find Academic Supervisors

Michael KinsellaView profile

Lecturer

• Organic Chemistry
• Green Chemistry
• Analytical Chemistry
• +5 more

Michael Kinsella is a Lecturer at South East Technological University (SETU) in the Department of Science Pharmaceutical and Molecular Biotechnology Research Centre. He serves as Programme Leader for the MSc in Analytical Science and is the institutional coordinator for SETU Waterford in the EU-CONEXUS initiative focused on Smart Urban Coastal Sustainability. His responsibilities include curriculum development, student mobility programs, and fostering research collaborations across the European network. Education: PhD in Organic & Analytical Chemistry from SETU (2011) Research Interests: Dr. Kinsella's work spans: Organic chemistry with emphasis on green synthesis methods Advanced analytical techniques (LC-MS) for bioanalysis and metabolomics Circular economy applications for aquatic waste valorization Novel characterization methods for pharmaceutical and biomolecular research His research contributes to UN Sustainable Development Goals through sustainable chemistry practices. Recent publications (2023-2024) demonstrate strong focus on: Sustainable/green chemistry methodologies Analytical technique development (qNMR, LC-MS) Waste-derived materials for environmental and pharmaceutical applications Antimicrobial natural products from marine sources Professional Activities: Chairperson of Irish Mass Spectrometry Society (IMSS) Extensive industry collaborations with pharmaceutical companies Co-Principal Investigator on Enterprise Ireland innovation project Programme manager for EU-funded research initiatives

Ida RobertsenView profile

Professor

• Pharmacokinetics
• Individualized Drug Treatment
• Therapeutic Drug Monitoring
• +7 more

Ida Robertsen is a Professor at the University of Oslo's School of Pharmacy, specifically within the Section for Pharmacology and Pharmaceutical Biosciences. Her primary focus is on pharmacokinetics research with special emphasis on individualized drug treatment, particularly in transplant medicine and obesity-related conditions. Dr. Robertsen earned her PhD in Pharmacological treatments and monitoring strategies to improve outcome in solid organ transplants from the School of Pharmacy, University of Oslo in 2014. Prior to this, she completed her Master in Pharmacy at the same institution in 2008, with research focused on Effects of rimonabant on cyclosporine A and tacrolimus pharmacokinetics in renal transplant recipients. Her research primarily centers on characterizing factors that contribute to variability in drug response. A significant portion of her work focuses on therapeutic drug monitoring of immunosuppressants in kidney transplant recipients, examining how factors like circadian rhythm, fasting status, and the microbiome affect drug metabolism and efficacy. She has also conducted extensive research on how obesity, bariatric surgery, and weight loss impact drug pharmacokinetics, particularly for drugs metabolized by cytochrome P450 enzymes. Her work often involves developing and validating novel sampling methods for therapeutic drug monitoring, including volumetric finger-prick self-sampling techniques. Dr. Robertsen has been instrumental in several major research projects, including the COCKTAIL study which examined the impact of body weight, low energy diet, and gastric bypass on drug bioavailability, cardiovascular risk factors, and metabolic biomarkers. She also leads research on the mechanistic understanding of the complex host-microbiome-drug interplay to optimize immunosuppressive drug therapy. Dr. Robertsen teaches several courses at the University of Oslo including FARM2110 - Pharmacotherapy 1, FARM4120 - Drug development, and FARM5150 - Applied pharmacokinetics and dosing in clinical practice. Her teaching reflects her research expertise in clinical pharmacology and therapeutic drug monitoring. She has published extensively in high-impact journals including Clinical Pharmacokinetics, Transplantation, Therapeutic Drug Monitoring, and Clinical Pharmacology and Therapeutics. Her recent work shows a growing focus on the intersection of microbiome science and pharmacokinetics, particularly how gut bacteria influence the metabolism of immunosuppressive drugs.

• Pharmacokinetics
• Bioanalysis
• Clinical Research
• +5 more

Dr. Steven Wallis serves as Head of Bioanalysis at the UQ Centre for Clinical Research, University of Queensland. With over 30 years of experience in clinical academic and pharmaceutical industry research, Dr. Wallis specializes in developing novel chromatographic methodologies for reliable drug quantification in diverse sample types, with particular expertise in applications for intensive care medicine. His leadership of the AMO bioanalysis laboratory has resulted in the measurement of over 100 drug analytes, including more than 60 antimicrobials. Dr. Wallis has participated in approximately 100 pharmacokinetic studies for the pharmaceutical industry, serving in roles ranging from analyst to study director and manager. His extensive publication record includes over 130 publications, demonstrating his significant contribution to the field of clinical pharmacology and bioanalysis. His research primarily focuses on pharmacokinetics, antibiotic dosing optimization, drug stability in various delivery systems, and the impact of specialized medical interventions (such as ECMO and renal replacement therapy) on drug behavior. Analysis of Dr. Wallis's recent publications (2023-2025) reveals a strong emphasis on optimizing antibiotic dosing regimens for special patient populations including those with obesity, critically ill patients, and patients receiving extracorporeal membrane oxygenation. His research frequently examines drug penetration into specific body compartments such as cerebrospinal fluid and interstitial fluid, and investigates alternative administration routes like subcutaneous delivery. The work demonstrates consistent translational focus, bridging sophisticated analytical methodology with direct clinical applications. Dr. Wallis maintains an extensive collaborative network, most notably with Jason A. Roberts, with whom he has co-authored numerous publications. His research often involves multi-center studies and international collaborations, reflecting the significance and reach of his work in the field of clinical pharmacology. As Head of Bioanalysis, he oversees a critical resource for numerous clinical research projects, providing high-quality bioanalytical support that meets rigorous scientific and regulatory standards.

• Photonics
• Biomedical Optics
• Raman Spectroscopy
• +3 more

Sara Abbasi is a Scientific employee within the Department of Applied Physics and Photonics at the Faculty of Engineering Sciences, Vrije Universiteit Brussel. She is affiliated with Brussels Photonics research group. Her work focuses on advancing photonics technologies for biomedical applications, particularly in Raman spectroscopy-based diagnostics and nano-optical systems design. She has contributed to innovations in SERS (Surface-enhanced Raman Scattering) platforms, including curved SERS substrates and integrated microlens arrays for parallel detection. Education details are not explicitly stated in the text, but her research activities from 2022-2025 and active participation in academic organizing committees indicate a strong academic trajectory. She has collaborated on projects involving hemoglobinopathy screening, pathogen identification, and machine learning integration with optical systems. Her research fingerprints prominently feature Raman spectroscopy (100% focus), hemoglobin analysis (75%), and liquid-phase optical systems. Notable contributions include developing novel microfabrication techniques for optical sensors and creating automated classification systems for biomedical spectra. Awards : Belgian Photonics Online Meetup 2022: Best poster prize (Jury Choice) Best Student paper award at SPIE Photonics Europe 2024 Advising & Collaboration : Co-organized the 38th International Symposium on Microscale Separations and Bioanalysis (MSB 2022) Collaborated with researchers like A. Feizpour, H. Thienpont, and PDIH Ottevaere on multiple projects Labs/Teams : Brussels Photonics Group, Applied Physics and Photonics Department labs

James RuslingView profile

Professor

• Bioanalytical Chemistry
• Biocatalysis
• Nanobiotechnology
• +7 more

James Rusling is a Professor at the University of Connecticut's Department of Chemistry, with a Ph.D. from Clarkson University and a B.S. from Drexel University. His research focuses on bioanalytical chemistry, biocatalysis, and nanobiotechnology, particularly for medical diagnostics and environmental health applications. Key projects include nanoparticle-based arrays for toxicity screening, LC-MS/MS studies of DNA damage, and 3D-printed platforms for cancer biomarker detection. Education: Ph.D. in Chemistry, Clarkson University; B.S. in Chemistry, Drexel University Research Interests: Medical diagnostics, environmental health, electrochemical sensing, CRISPR-based assays, and nanomaterials for bioanalysis Recent trends in his publications highlight CRISPR technology for Alzheimer's and cancer diagnostics, microfluidic immunoarrays for ultrasensitive protein detection, and advanced biocatalytic systems for chiral oxidation. His work also addresses challenges in PFAS sensing and wearable sensor materials. Dr. Rusling's lab employs multidisciplinary approaches combining electrochemistry, nanotechnology, and molecular biology to tackle societal issues in disease detection and environmental monitoring.

• Functional genetic variation
• Type 2 diabetes
• CRISPR genome editing
• +7 more

Sebastian Kalamajski is a Senior Lecturer in Biomedical Laboratory Science at the Faculty of Natural Science, Department of Bioanalysis. His research bridges experimental genetics and data science to study functional genetic variation impacting human health, with primary focus on type 2 diabetes and obesity-related metabolic disorders. Research Interests: CRISPR-based allele substitution in fat and beta cells Identification of causal genetic variants for disease phenotypes Adipose tissue hyperplasia and insulin responsiveness International collaborations with Lund University, Broad Institute/Harvard, and Ulm University Integration of data science and experimental methodologies Recent Publication Trends: 2024 articles examine social trust genetics, PPARGC1B variants in adiposity, and molecular modeling of genetic risks using stem cells. Earlier works (2023) focus on phenome-wide analyses of obesity-diabetes discordance. Academic Activities: Peer-review work for journals: Pharmacogenomics , Diabetologia , and Animal Models and Experimental Medicine Supervision of PhD students and research projects Examination committee leadership

• Pharmacokinetics
• Drug Metabolism
• Pharmaceutical Analysis
• +5 more

Siva Rama Raju Kanumuri is an Assistant Scientist in the Department of Pharmaceutics at the University of Florida, Gainesville, affiliated with the CTSI-Translational Drug Development Core. He holds a Ph.D. from CSIR-Central Drug Research Institute and completed postdoctoral training at the University of Cincinnati (2017-2019) and University of Florida (2019-2022). His research focuses on pharmacokinetics, drug metabolism, and ADMET studies for small molecules and natural products, with emphasis on optimizing drug development through metabolic stability, transport, and permeability analysis. Education: Ph.D. (2016) from CSIR-Central Drug Research Institute/Academy of Scientific and Innovative Research; M.S. (2011) in Pharmaceutics from NIPER Raebareli; B.Pharm. (2008) from Andhra University. He also completed a PG Diploma in Patent Law (2014-2015) from NALSAR University of Law. Research interests include bioanalysis, drug metabolism, PK-PD modeling, and clinical pharmacokinetics. His work spans preclinical to clinical studies, with a focus on natural products like kratom, kava, and cannabinoids. Key methodologies include UPLC-MS/MS, pharmacokinetic modeling, and in vitro/in vivo toxicity assessments. Publications highlight studies on kratom alkaloids (e.g., mitragynine, 7-hydroxymitragynine), cannabidiol interactions, and drug metabolism pathways. Recent work examines kratom’s effects on human behavior and driving, alongside mechanistic studies on α9 nicotinic receptors and CaV2.2 channel blockers. Major Awards: ISSX Travel Award (2015), CSIR Senior Research Fellowship (2013-2016), Dr. P.D. Sethi Award (2012). His lab contributes to translational research, bridging preclinical drug development and clinical applications. Ongoing projects explore kratom’s pharmacology, drug-drug interactions, and regulatory-compliant analytical methods for cannabis and industrial hemp.

Jayne WuView profile

Professor

• Microfluidics
• Bioelectronics
• Optofluidics
• +5 more

Jayne Wu is a Professor in the Min H. Kao Department of Electrical Engineering and Computer Science at the University of Tennessee, Knoxville, affiliated with the Tickle College of Engineering. She serves as Director of the Initiative of PON/POC Nano-bio-sensing and is an affiliated faculty member at the Institute of Biomedical Engineering. Her research focuses on microfluidics, bioelectronics, and nanobiosensing, with applications in environmental monitoring, clinical diagnostics, and portable devices. Education includes a PhD in Electrical Engineering (University of Notre Dame, 2004) and prior degrees from institutions in China, including a PhD in Solid-State Electronics (2001) and BEng (1993). Her lab, the Micro Analysis Systems Laboratory, develops innovative biosensors for real-time detection of pathogens, toxins, and biomarkers. Research interests span AC electrokinetics for bio-nano-applications, wearable/implantable devices, and MEMS power systems. She has advised multiple PhD and Master’s students, including notable alumnus Nazmul Islam (Assistant Professor at Northern Arizona University). Collaborations include visiting scholars and industry partnerships (e.g., Meridian Biosciences, Purdue University). Key contributions include capacitive aptasensors for ultra-sensitive detection of heavy metals, pathogens, and microRNAs, as well as lab-on-a-chip systems for resource-limited settings. Her work emphasizes low-cost, rapid, and field-deployable solutions for global health challenges.

CHUI Wai KeungView profile

Associate Professor

• Pharmaceutical Biotechnology
• Medicinal Chemistry
• Drug Design
• +5 more

A/Prof CHUI Wai Keung is an Associate Professor in the Department of Pharmacy and Pharmaceutical Sciences at the National University of Singapore (NUS), affiliated with the Faculty of Science. He holds a BSc (Pharm) (Hons) and PhD from NUS, and a PhD from Aston University, Birmingham, UK. His research focuses on drug design, particularly developing anticonvulsant and antifolate agents using computational modeling, combinatorial synthesis, and biological assays. He also specializes in botanical drug standardization, chiral separation of drug molecules, and bioanalysis method development. Teaching responsibilities include modules on Pharmaceutical Biotechnology, Bioorganic Principles of Medicinal Chemistry, and Natural Products. His work bridges pharmaceutical sciences with healthcare innovation, emphasizing drug-like property optimization and translational research. No specific scientific awards or grants are listed in the provided information. His research location is Block S4A, Level 3, 18 Science Drive 4, Singapore.

• Analytical Chemistry
• Biomedical Engineering
• Nanotechnology
• +3 more

Professor Tony Cass is a Professor of Chemical Biology at Imperial College London's Department of Chemistry and Institute of Biomedical Engineering. He is a Fellow of the Royal Society of Chemistry and Society of Biology. His research focuses on analytical biotechnology, biosensors, and microfabricated devices, with applications in clinical and environmental analysis. Key projects include pioneering electronic blood glucose measurement systems (commercialized by Abbott Diagnostics) and developing microneedle-based biosensors for real-time drug monitoring and diagnostics. Education: Degrees from the Universities of York and Oxford in chemistry. Affiliations include the Agri Futures Lab, CDT in Chemical Biology, CRUK Convergence Science Centre, and Institute of Chemical Biology. He has founded Bio Nano Consulting Ltd. and AquAffirm, and advises companies like PlastiCell and SabiliTech. Over 150 papers and 3 books to date, with editorial roles in Nanobioscience and IET Proceedings Nanobiotechnology . Research interests span engineered proteins/nucleic acids in nanomaterials, antimicrobial optimization, and sensor-driven healthcare. Awards include the Royal Society Mullard Medal (with Prof. Hill and Dr. Green) and Chemical Landmark Award.

• Pharmaceutical Sciences
• Clinical Pharmacy
• Transplant Pharmacology
• +5 more

Dr. Amelia Cossart serves as an Honorary Lecturer at The University of Queensland's School of Pharmacy and Pharmaceutical Sciences, contributing to Australia's leading pharmacy education and research institution through specialized clinical investigations. Her academic foundation includes a PhD from The University of Queensland (2022), where her thesis "Optimising immunosuppressant medicines in elderly kidney transplant recipients" established her research trajectory. This doctoral work examined medication adherence barriers and pharmacokinetic challenges in aging transplant populations using mixed-methods approaches. Dr. Cossart's research program centers on critical gaps in transplant pharmacotherapy, with primary emphases on: Age-related pharmacokinetic variations in immunosuppressant drugs Medication adherence barriers among elderly transplant recipients Therapeutic drug monitoring optimization Clinical pharmacy service evaluation Patient-reported outcome measurement Her methodological approach integrates quantitative registry analyses with qualitative patient interviews to develop clinically actionable insights for complex medication management scenarios. Analysis of her 15 journal publications (2019-2025) reveals consistent thematic focus on kidney transplantation, with 73% specifically addressing elderly patient populations. Key evolving trends include expanding from pharmacokinetic studies (2019-2021) toward health services research (2022-2025), including digital prescription services and pandemic impacts on substance use. Her work maintains strong clinical relevance through partnerships with transplant centers across Australia and New Zealand. Dr. Cossart actively collaborates with multi-disciplinary teams including the Safe and Effective Medication Collaborative at UQ, working alongside nephrologists, surgeons, and pharmacists to translate research into practice improvements for vulnerable transplant patients.

Daniel T. ChiuView profile

Professor

• Analytical Chemistry
• Biophysics
• Chemical Biology
• +5 more

Daniel T. Chiu is the A. Bruce Montgomery Professor of Chemistry, Endowed Professor of Analytical Chemistry, and Washington Research Foundation Professor at the University of Washington. He is also a Professor of Bioengineering and a member of the Cancer Consortium at Fred Hutchinson Cancer Research Center. His roles emphasize interdisciplinary research in nanomaterials, microfluidics, and bioanalytical instrumentation. Dr. Chiu holds a B.A. in Neurobiology and a B.S. in Chemistry from the University of California, Berkeley (1993), and a Ph.D. in Chemistry from Stanford University (1998). He completed postdoctoral research at Harvard University before joining UW in 2000 as an Assistant Professor of Chemistry. His research interests focus on innovative technologies for ultra-sensitive bioanalysis, including fluorescent nanomaterials, single-molecule studies, and point-of-care diagnostics. He has developed cutting-edge tools for single-cell biology and digital assays, leveraging expertise in materials science and biophysics. Dr. Chiu has been recognized with prestigious awards such as the American Chemical Society National Fresenius Award and Pittcon Achievement Award. He is an AAAS Fellow and a Keck Distinguished Young Scholar in Biomedical Research. He is actively advising graduate students and has secured extensive grants. His work bridges chemistry, bioengineering, and medical applications, contributing to advancements in healthcare and diagnostics. He is affiliated with the Department of Chemistry and collaborates through the Cancer Consortium, fostering interdisciplinary research initiatives. Dr. Chiu’s laboratory focuses on integrating nanotechnology and microfluidics for biomedical applications. He maintains a strong presence in teaching and mentoring, contributing to both the Chemistry and Bioengineering programs at UW.

Peter HorvatovichView profile

Professor

• Computational Mass Spectrometry
• Proteomics
• Bioinformatics
• +4 more

Peter Horvatovich is a Full Professor in Computational Mass Spectrometry and Head of the Department of Analytical Biochemistry at the University of Groningen. He holds affiliations with the Groningen Research Institute of Pharmacy (GRIP) and leads the Interfaculty Mass Spectrometry Center. His roles include Secretary General of the Chromosome-Centric Human Proteome Project (C-HPP) and PI for Chromosome 5 research, as well as Program Leader of the Medicinal Chemistry and Bioanalysis (MCB) program. Education: PhD in Analytical Chemistry (2001, Louis Pasteur University & Szent István University), MSc in Physical Chemistry (1997, Louis Pasteur University), and BSc in Environmental Analytical Chemistry (1996, Eötvös Loránd University). Research focuses on computational mass spectrometry, proteogenomics, and biomarker discovery. Key areas include data integration for LC-MS-based proteomics, cancer biomarkers (e.g., melanoma), and extracellular matrix analysis in COPD. He develops tools like PASTAQ for MS data quantification and collaborates on projects like the European Cancer Moonshot Lund Center. Teaching includes biostatistics and proteomics courses for pharmacy and master’s students. He supervises PhD and master’s students in proteomics, bioinformatics, and analytical chemistry. Notable projects involve lung tissue proteogenomics, head/neck cancer protein profiling, and chemoproteomic studies of glycation end-products. Labs/Teams: Leads the Horvatovich Lab, collaborates with the European Cancer Moonshot Lund Center, and manages the Interfaculty Mass Spectrometry Core Facility. Active in open-source software development (GitHub: HorvatovichLab).

D.J. (Daan) TouwView profile

Professor

• Bioanalysis
• Pharmacokinetics
• Pharmacometrics
• +3 more

Prof. D.J. (Daan) Touw is a Professor of Bioanalysis, Therapeutic Drug Monitoring, and Clinical Toxicology at the University of Groningen's Faculty of Science and Engineering. He serves as Head of the Laboratory of Clinical Pharmacy and Pharmacology at the UMCG. His expertise spans clinical pharmacology, toxicology, and hospital pharmacy, with roles including European Registered Toxicologist (ERT) and membership in national/international committees like the Dutch Working Party Antibiotic Policy and European Pharmacopoeia Expert Groups (Water & Dialysis). Education: MSc in Pharmacy from Leiden University (1984), PhD in Pharmacokinetics (1996) under Prof. D.D. Breimer. Career milestones include roles as Head of Clinical Pharmacy Labs at VU Amsterdam (1995–2000) and Haagse Ziekenhuizen (2000–2013). Research: Focuses on pharmacokinetics, bioanalysis, and clinical toxicology. Key interests include optimizing antibiotic therapy in cystic fibrosis, toxicology of emerging drugs (e.g., 'tranq'), and pharmacogenetic guidelines for statins/sulfonylureas. Awards: Recipient of national teaching awards for 'Best First-Year Course' (2022–2024) and NVKC abstract prize (2025). Active in public engagement, addressing media on drug trends (e.g., tranq, counterfeit pills). Teaching: Leads courses in Pharmacokinetics, Clinical Toxicology, and Hospital Pharmacy. Supervises advanced pharmacokinetics training and coordinates clinical toxicology education.

• Microfluidics
• Lab-on-a-chip Technology
• Analytical Chemistry
• +3 more

Prof. Sabeth Verpoorte is a Professor at the University of Groningen's Faculty of Science and Engineering, affiliated with Pharmaceutical Analysis and Medicinal Chemistry and Bioanalysis (MCB) at the UMCG. She leads the Graduate School of Science and Engineering and chairs multiple scientific advisory boards. Her research focuses on microfluidics, lab-on-a-chip systems, and organ-on-a-chip models for biomedical applications. Education: Doctorate in Chemistry (not explicitly stated in texts, inferred from academic rank and roles). Research Interests: Microfluidic device development, organ-on-a-chip technology for disease modeling, analytical chemistry in biomedical systems, and drug delivery systems. Her work spans interdisciplinary collaborations in engineering, chemistry, and medicine. Articles Overview: Recent studies include electrochemical flow reactors, SERS-based biosensors, and liver toxicity analysis. Her articles bridge microfluidics with clinical applications, emphasizing in vitro models for drug testing and disease mechanisms. Awards: Recognized as a Fellow of the European Alliance for Medical and Biological Engineering (2018), Society for Laboratory Automation (2018), and Royal Society of Chemistry (2004), plus a ZonMw Neuro-Chip grant (2017). Grants & Advising: Secured major grants like Neuro-Chip. Supervised interdisciplinary projects on mitochondrial transplantation and neurobiology. Active in graduate education as Graduate School Director. Labs/Teams: Leads labs developing organ-on-a-chip systems and collaborative projects with industry partners like Seyonic SA. Key facilities include microfabrication labs and analytical chemistry platforms.